Our Services
Medical Information
Helpful Resources
Published on: 9/23/2026
Most adults who receive an RSV vaccine (Arexvy, Abrysvo, or mResvia) experience only mild, short-lived reactions, with the most common being injection site pain, fatigue, muscle aches, headache, joint pain, and sometimes mild fever or nausea that typically resolve within one to three days. Rarer effects reported in clinical trials and post-marketing surveillance include allergic reactions and, very uncommonly, Guillain-Barré syndrome, which is why symptom severity and timing matter. Your age, immune status, medications, and whether you received another vaccine at the same visit can all change what you feel and how long it lasts. There are several important factors to consider, including which symptoms warrant a call to your doctor versus simple rest and fluids, so review the complete details below before deciding your next step. If you are feeling unwell after your shot and are unsure whether it is a normal vaccine reaction or something else, a free, instant, online symptom check can help you sort through your symptoms in a few minutes and understand whether self-care, a virtual visit, or urgent evaluation makes the most sense right now.
Last reviewed for medical accuracy: 09/23/2026
Respiratory Syncytial Virus (RSV) is a frequent cause of lower respiratory tract illness, especially in older adults and those with certain health conditions. In 2023, the U.S. Food and Drug Administration (FDA) approved two RSV vaccines—Arexvy (GSK) and Abrysvo (Pfizer)—for use in adults aged 60 years and older. As with any vaccine, you may experience some side effects. Understanding RSV vaccine side effects in adults can help you prepare and recognize what’s normal versus when to seek medical attention.
Clinical trials for both Arexvy and Abrysvo enrolled tens of thousands of participants aged 60+ and tracked reactions within 7 days of vaccination, as well as any serious events over several months. Overall, both vaccines showed similar safety profiles:
Most adults report mild-to-moderate discomfort at the injection site. Typical rates in trials included:
These reactions usually begin within a few hours and resolve in 1–3 days without intervention. Applying a cool, damp cloth and keeping the arm mobile can ease discomfort.
Systemic reactions are less common and typically mild. Across studies, participants experienced:
Most systemic side effects start within 24 hours, peak at 48 hours, and subside by day 3 or 4. Staying hydrated, resting, and taking over-the-counter pain relievers (if approved by your doctor) can help manage these symptoms.
Although uncommon, more serious reactions have been monitored:
Because anaphylaxis can be life-threatening, vaccination sites are equipped to respond, and recipients are typically observed for 15–30 minutes post-injection.
Certain groups may have a slightly higher chance of side effects:
If you’re unwell on the day scheduled for vaccination, discuss with your healthcare provider whether to postpone.
Most RSV vaccine side effects in adults are mild and self-limiting. Here’s how to handle them:
Though most reactions are mild, certain symptoms warrant prompt action:
Signs of severe allergic reaction (within minutes to hours):
• Hives or widespread rash
• Difficulty breathing, wheezing
• Swelling of face, lips, tongue or throat
• Dizziness or loss of consciousness
Call 911 or go to the nearest emergency department immediately.
High or persistent fever (>104°F/40°C) lasting more than 48 hours.
Severe headache unrelieved by over-the-counter pain medication.
Progressive weakness or numbness in the limbs.
Any symptom that feels alarming or unusual to you.
If you’re unsure about your symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to guide your next steps.
For most adults, the protective benefits of RSV vaccination far outweigh the temporary discomfort of side effects.
Understanding rsv vaccine side effects in adults empowers you to make informed decisions about your health. While mild side effects like injection-site pain, fatigue, and headache are common, serious reactions are extremely rare. By recognizing normal post-vaccine symptoms—and knowing when to seek help—you can confidently protect yourself against RSV.
If you experience any signs of a severe allergic reaction or anything that feels life-threatening, call 911 or go to the nearest emergency department without delay. For non-emergency concerns, talk with your healthcare provider to determine the best next steps.
Stay proactive and informed—your health matters. Speak to a doctor about vaccination and any side effects that concern you.
(References)
* Qiu X, Xu S, Lu Y, Luo Z, Yan Y, Wang C, Ji J. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev. 2022 Dec;68:37-53. doi: 10.1016/j.cytogfr.2022.10.001. Epub 2022 Oct 13. PMID: 36280532.
* Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V, AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. PMID: 36791160.
* Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, Rämet M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Castillo Villa G, Ingilizova M, Eiras D, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gurtman A, Gruber WC, Schmoele-Thoma B, RENOIR Clinical Trial Group. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med. 2023 Apr 20;388(16):1465-1477. doi: 10.1056/NEJMoa2213836. Epub 2023 Apr 5. PMID: 37018468.
* Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, Baker J, Pérez Marc G, Radley D, Shittu E, Glanternik J, Snaggs H, Baber J, Zachariah P, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Duron Padilla M, Richmond PC, Koury K, Schneider K, Kalinina EV, Cooper D, Jansen KU, Anderson AS, Swanson KA, Gruber WC, Gurtman A, MATISSE Study Group. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. PMID: 37018474.
* Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D, AReSVi-006 Study Group. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744. doi: 10.1093/cid/ciae010. PMID: 38253338; PMCID: PMC11175669.
* Phijffer EW, de Bruin O, Ahmadizar F, Bont LJ, Van der Maas NA, Sturkenboom MC, Wildenbeest JG, Bloemenkamp KW. Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes. Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. doi: 10.1002/14651858.CD015134.pub2. Epub 2024 May 2. PMID: 38695784; PMCID: PMC11064886.
* Roman F, Burny W, Ceregido MA, Laupèze B, Temmerman ST, Warter L, Coccia M. Adjuvant system AS01: from mode of action to effective vaccines. Expert Rev Vaccines. 2024 Jan-Dec;23(1):715-729. doi: 10.1080/14760584.2024.2382725. Epub 2024 Aug 5. PMID: 39042099.
* Simões EAF, Pahud BA, Madhi SA, Kampmann B, Shittu E, Radley D, Llapur C, Baker J, Pérez Marc G, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Padilla MD, Richmond PC, Sarwar UN, Baber J, Koury K, Lino MM, Kalinina EV, Li W, Cooper D, Anderson AS, Swanson KA, Gurtman A, Munjal I, MATISSE (Maternal Immunization Study for Safety and Efficacy) Clinical Trial Group. Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025 Feb 1;145(2):157-167. doi: 10.1097/AOG.0000000000005816. Epub 2025 Jan 2. PMID: 39746212; PMCID: PMC11731064.
* Kelleher K, Subramaniam N, Drysdale SB. The recent landscape of RSV vaccine research. Ther Adv Vaccines Immunother. 2025;13:25151355241310601. doi: 10.1177/25151355241310601. Epub 2025 Jan 10. PMID: 39802673; PMCID: PMC11724408.
* Scott J, Abers MS, Marwah HK, McCann NC, Meyerowitz EA, Richterman A, Fleming DF, Holmes EJ, Moat LE, Redepenning SG, Smith EA, Stoddart CJ, Sundaram ME, Ulrich AK, Alba C, Anderson CJ, Arpey MK, Borre E, Ladines-Lim J, Mehr AJ, Rich K, Watts C, Basta NE, Jarolimova J, Walensky RP, Dugdale CM. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026. N Engl J Med. 2025 Dec 4;393(22):2221-2242. doi: 10.1056/NEJMsa2514268. Epub 2025 Oct 29. PMID: 41160817.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.